Status:
COMPLETED
Prediction of Acute Kidney Injury in Patients With COVID-19
Lead Sponsor:
University Hospital Muenster
Conditions:
Acute Kidney Injury
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
The two biomarkers determined in urine, "Tissue Inhibitor of Metalloproteinases 2 (TIMP-2)" and "Insulin-like Growth Factor-Binding Protein 7 (IGFBP7)", can indicate the occurrence of Acute kidney inj...
Detailed Description
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is rapidly spreading around the world. The current outbreak of infections with SARS-CoV-2 is termed Coronavirus Disease 2019 (COVID-19). Tw...
Eligibility Criteria
Inclusion
- Moderate or severe ARDS according to the Berlin definition
- SARS-CoV2 positive test
- Age ≥ 18 years
- Informed consent
Exclusion
- Pre-existing AKI
- Severe CKD with eGFR\<20ml/min
- Chronic dialysis dependency
- Kidney transplant within the last 12 months
- Pregnancy, breastfeeding
- Persons with any kind of dependency on the investigator or employed by the sponsor or investigator.
Key Trial Info
Start Date :
June 22 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04406688
Start Date
June 22 2020
End Date
March 31 2022
Last Update
November 7 2022
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Münster
Münster, Germany
2
Papa Giovanni XXIII Hospital
Bergamo, Italy
3
San Bortolo Hospital
Vicenza, Italy
4
Centro Hospitalar e Universitário de Coimbra
Coimbra, Portugal